Results 101 to 110 of about 22,802 (228)
CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.This registry‐based analysis of 1183 MS clinical trials (2004–2024) shows sustained global activity and a marked increase in mainland China after 2018, predominantly driven by late‐phase and bioequivalence studies. Trial density varied across regions, and IFNAR, CD20, and S1PR1 were the most frequently investigated targets. ABSTRACT Background Multiple
Chaoyang Chen +7 more
wiley +1 more source
Inter-strain differences of serotonergic inhibitory pain control in inbred mice [PDF]
, 2010 Background: Descending inhibitory pain control contributes to the endogenous defense against chronic pain and involves noradrenergic and serotonergic systems.
Wijnvoord, Nina +5 more
core +2 more sources
Serotonergic modulation of suicidal behaviour : integrating preclinical data with clinical practice and psychotherapy [PDF]
, 2013 Many studies have provided important information regarding the anatomy, development and functional organization of the 5-HT system and the alterations in this system that are present within the brain of the suicidal patient.
Boulougouris, Vasileious +4 more
core +1 more source
The structural diversity of psychedelic drug actions revealed
Nature CommunicationsThere is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized
Ryan H. Gumpper +13 more
doaj +1 more source
Puerarin Acts Through Brain Serotonergic Mechanisms to Induce Thermal Effects
Journal of Pharmacological Sciences, 2004 The present study was attempted to investigate the effect of puerarin, an isoflavone compound isolated from Pueraria lobata, on both the basal body temperature and pyrogenic fever in unanesthetized, restrained rats.
Fu-Shin Chueh +3 more
doaj +1 more source
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT1A receptors but not 5-HT2A receptors [PDF]
, 2013 Atypical antipsychotic drugs (APDs) increase dopamine (DA) release in prefrontal cortex (PFC), an effect probably mediated by the direct or indirect activation of the 5-HT1A receptor (5-HT1AR).
Artigas, Francesc +7 more
core +2 more sources
Neural Regeneration Research, 2016 Previous studies suggest that serotonin (5-HT) might interact with brain-derived neurotrophic factor (BDNF) during the stress response. However, the relationship between 5-HT and BDNF expression under purely psychological stress is unclear. In this study,
De-guo Jiang +8 more
doaj +1 more source
What's a brain: neuroanatomy and neurochemistry of anxiety disorders in dogs [PDF]
, 2011 This review deals with the neurocircuitry of fear and anxiety disorders, with the focus on neuroanatomy and neurochemistry. This knowledge is required to correctly diagnose and treat dogs with anxiety-related behavioral disorders.
Audenaert, Kurt +6 more
core +1 more source
Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) [PDF]
, 2015 N-2-methoxybenzyl-phenethylamines (NBOMe drugs) are newly used psychoactive substances with poorly defined pharmacological properties. The aim of the present study was to characterize the receptor binding profiles of a series of NBOMe drugs compared with
Buchy, Danièle +5 more
core +1 more source
Acta Pharmaceutica Sinica BG protein-coupled receptors (GPCRs) represent key drug targets, with approximately 30%–40% of all medications acting on these receptors. Recent advancements have uncovered the complexity of GPCR signaling, including biased signaling, which allows ...
Michał K. Jastrzębski +11 more
doaj +1 more source